Skip To Main Content
Kuan-Hsiang Gary on Muck Rack

Kuan-Hsiang Gary

As seen in: Arthritis Research & Therapy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Kuan-Hsiang Gary’s profile

Articles by Kuan-Hsiang Gary

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study | Arthritis Research & Therapy | Full Text

|
By Vivian Bykerk, Thomas W. J, Musculoskeletal Medicine, Kuan-Hsiang Gary
| Arthritis Research & Therapy Verified
Study design Full details of the study design have been published previously [29]. Briefly, AVERT-2 (NCT02504268) was a phase IIIb, 132-week, randomized, double-blind, placebo-controlled study of MTX-naive, anti-citrullinated protein antibody (ACPA)-positive patients with active, early RA.
Open in Who Shared Issue with article?

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study (pdf) | Paperity

|
By Thomas W. J, Kuan-Hsiang Gary
| paperity.org
Arthritis Research & Therapy, Apr 2023 This is a preview of a remote PDF: https://arthritis-research.biomedcentral.com/counter/pdf/10.1186/s13075-023-03038-2 Emery, Paul, Tanaka, Yoshiya, Bykerk, Vivian P., Bingham, Clifton O., Huizinga, Thomas W. J., Citera, Gustavo, Huang, Kuan-Hsiang Gary, Wu, Chun, Connolly, Sean E., Elbez, Yedid, Wong, Robert, Lozenski, Karissa, Fleischmann, Roy. , Arthritis Research & Therapy, 2023, pp. 1-13, Volume 25, Issue 1, DOI: 10.1186/s13075-023-03038-2
Open in Who Shared Issue with article?
Show More